• SK Bioscience’s third-quarter 2026 operating loss narrowed 42.1% year over year to KRW 11.22 billion.
• Revenue rose 21% year over year to KRW 182.44 billion.
• Net profit fell 43% year over year to KRW 12.01 billion.
• The result reversed a second-quarter net loss of KRW 14.09 billion.
• Nine-month net results swung to a KRW 38.24 billion loss from a year-earlier profit of KRW 232 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SK Bioscience Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261105800512), on November 05, 2026, and is solely responsible for the information contained therein.